Fundz
Funding, M&A, exec moves and hiring — every signal, the moment it breaks.See plans →

Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease.

PRIVATEAug 05, 2026•3 days ago

Amount Raised

$46 Million

Round Type

Series B

GlasgowBiotechnology

Investors

RocheScottish National Investment Bank

Description

Mironid, a biopharmaceutical company, has raised $46 million in a Series B funding round. The investment will support the clinical development of its treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). With funding from the Scottish National Investment Bank and Roche, the company aims to transform treatment for patients. This financing validates their approach in treating rare kidney diseases.

Company Information

Company

Mironid

Location

Glasgow, Kentucky, United States

About

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.

Related People

Suggested for you
1 contact
Verified contactsNo contacts on file at Mironid yet.
Predictive Intelligence
Strategic

ML-powered predictions for Mironid's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching Mironid? See every signal — funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan